Products

Liposomal Iron, B12, Folic acid and Vitamin D3-Administered as Transdermal oil

• Infant oil massage has been a traditional practice in India and MKPPL plans to leverage this practice to implement a technological innovation for delivery of micronutrients using fortified oils.
• MKPPL have developed safe nano particles that encapsulate micronutrients and interact with the outermost layer of skin to enhance penetration and can be delivered through an oil platform.
• Liposomal nano particle approach can be utilised for administering various vitamins through the dermal route and for delivering various antibiotics and anti –inflammatory agents through topical applications.
• Offer complete technical package for registrations in all regulated/semi regulated markets.

Mebeverine HCL Extended Release Pellets – Suitable for filling in 135mg & 200mg Capsules.

• MKPPL achieved the desired sustained release profile equivalent to innovator
• Mebeverine is an antispasmodic medicine which is taken to relieve bloating and cramp pain in the lower abdomen. These symptoms are commonly associated with the gastrointestinal condition called irritable bowel syndrome.
• MKPPL aims to deliver Mebeverine as an inhibitor of calcium-depot replenishment. Musculotropic compounds act directly on the gut muscles at the cellular level to relax them. This relieves painful muscle spasms of the gut without affecting its normal motility.
• Offer complete technical package for registrations in all regulated/semi regulated markets.

MK-VitFe – Transdermal Liposomal Lotion for Topical Massage

Product contains API of Ferrous Bisglycinate (Elemental Iron), Vitamin B12, Vitamin D3, Folic acid

Benefits of Transdermal Liposomal Lotion:

• Easy for application
• Skin friendly, Non-irritant
• Bypass first pass effect
• Liposomal based formulation possesses advantage over conventional lotion, due to very small particle size they can easily penetrate through the skin uppermost layer.
• Convenient for unconscious patients or patients to have difficulty in oral administration.

Mesalamine SR Pellets / Granules 

Mesalamine is a drug used for treating ulcerative colitis. Although the exact mechanism of mesalamine is not known it is believed to be reducing the inflammation in the colon through systemic action.

• Mesalamine is an anti-inflammatory agent used to treat ulcerative colitis. Mesalamine comes as a Delayed-release tablet, Delayed-release capsule, Controlled-release capsule, Extended-release capsule, Suppositories.
• Mesalamine ER Pellets have dissolution time of 8 hours and are released as per the USP Monograph.
• We do offer development services in case of a requirement for different formulation/dosage/strength
• Offer complete technical package for registrations in all regulated/semi regulated markets
• Products protected by ongoing Patents are not offered by MKPPL.

Memantine HCL ER Pellets- Suitable for filling in Capsules- 14mg, 21mg & 28mg.

• Release pattern compared with innovator Namenda XR.
• MKPPL extended release pellets are the mixture of two types of pellets which are blended together to final strength of 10.56% w/w. this strength is dose equivalent and same pellets are used for different doses by changing the fill weight and capsule size for respective doses.
• The formulation is based on the dispersion of drug in purified water and homogenization to reduce the particle size of active ingredient and to achieve the dissolution equivalent to innovator.
• Offer complete technical package for registrations in all regulated/semi regulated markets.

Mycophenolate mofetil (MMF) is a immunosuppressant and product of mycophenolic acid, used extensively in transplant medicine, and it may play an increasing role in autoimmune disease. MMF has been introduced as a novel immunosuppressive agent in systemic lupus erythematosus (SLE), often in patients intolerant of or resistant to conventional immunosuppressive regimens.

Omeprazole Pellets 8.5%, 10%, 20%, 22%, 22.5%, 30% – Suitable for Capsules (Dose: 10 mg, 20 mg, 40 mg)

Omeprazole is a widely used proton pump inhibitor that is used in the treatment of peptic ulcers.

• Omeprazole delayed-release oral suspension is a proton pump inhibitor (PPI). It works by decreasing the amount of acid produced in the stomach.
• The product developed is comparable with innovator with respect to dissolution profile of the marketed product.
• We offer complete technical package for registrations in all regulated/semi regulated markets
• The DMF file for Omeprazole Pellets 8.5% is submitted to the USFDA and is awaiting review.
  The EDMF file for Omeprazole Pellets 8.5% is submitted with the National Authorities is Greece and Romania and is awaiting review.
• Omeprazole Pellets 8.5% BA/BE Studies have been successfully completed by the end users.
• Products protected by ongoing Patents are not offered by MKPPL.

Orlistat Pellets 50% – Ready to Fill Into Capsules (Dose: 60 mg, 120 mg)

Orlistat is a lipase inhibitor for obesity management that acts by inhibiting the absorption of dietary fats. Orlistat can also help to reduce risk factors, such as high blood pressure, high cholesterol and high blood sugar which, if not treated, could lead to other diseases such as hypertension and diabetes.

• MKPPL has developed Orlistat pellets equivalent to innovator product using aqueous technology.
• Multimedia Dissolution Profile is compared with Marketed Product and similarity results were within limits in all media.
• We do offer development services in case of a requirement for different formulation/dosage/strength
• Offer complete technical package for registrations in all regulated/semi regulated markets
• MKPPL offers a patent non-infringing product.

Paclitaxel Albumin Encapsulated – Available as Lyophilized powder/100mg vials & Nano Particles (Patent Non infringing)

Paclitaxel Nano-Pellets for Injection. Paclitaxel is a mitotic inhibitor drip used in the treatment of cancer.

• MKPPL is the only the sixth company in India to have developed successfully nab-paclitaxel, the other companies being Cipla, Sun Pharma, Cadila-Zydus, Intas and Natco.
• The particle size and the encapsulation efficiency have matched the innovator’s specifications.
• In vitro cell line studies have shown that the activity is comparable to the innovator.
• Offer complete technical package for registrations in all regulated/semi regulated markets.

Paclitaxel (protein-bound particles) for Injectable Suspension

• Nab Paclitaxel is a ground-breaking chemotherapy medication.
• It is uniquely formulated as an albumin-bound nanoparticle, which enhances both its efficacy and safety.
• Nab Paclitaxel is utilized in the treatment of breast cancer, pancreatic cancer, and non-small cell lung cancer.
• Administration is typically via intravenous infusion.

Revolutionizing Cancer Care with Nab Paclitaxel Treatment

Advantages of Nab Paclitaxel:

• Enhanced Solubility: The nanoparticle form of Nab Paclitaxel improves its solubility in water, facilitating easier administration.
• Targeted Delivery: Nano-sized particles exhibit a preference for accumulating at tumor sites, boosting the drug’s effectiveness.
• Reduced Side Effects: Nab Paclitaxel nanoparticles evade recognition by healthy tissues, thereby minimizing adverse
  effects.
• Higher Dosing: This enables the use of higher maximum tolerated doses (MTD).
• Improved Pharmacokinetics: Longer half-life and superior tumor accumulation.

The Significance of Encapsulation:

• Encapsulation of paclitaxel is crucial for precise targeting while minimizing side effects.
• Conventional systemic administration affects healthy cells throughout the body.
• Encapsulation guarantees that the drug efficiently reaches the tumor site.

Pancreatin-Delayed Release Pellets-Suitable for 10000, 25000, 40000 iu unit Caps (Creon)

• Release pattern and comparative study done with innovator
• MKPPL product advantages include:
• Smaller size of pellets.
• Spherical shaped pellets compared to the innovator Creon.
• Higher drug loading possible to meet 50,000 iu lipase activity.

Offer complete technical package for registrations in all regulated/semi regulated markets.